
retifanlimab

mercal sell carsinomayude chikilsaykkaayi upayogikkunna cancer virudha marunnaan sainis enna brand naamatthil vilkkunna retifanlimab. monoclonal antibody thadayunna oru prograam cheytha deth risapttar-1 (pii. dii-1) aanu retifanlimab.
2023 maarchil amerikkayil ithu vaidyashaasthraparamaaya upayogathinaayi amgeekarichu.
medical upayogangal.
metaastaattik allengil aavarthichulla praadeshikamaayi vipulamaaya mercal sell carcinoma ulla muthirnnavarude chikilsaykkaayi retifanlimab soochippikkunnu.
charithram.
us phudu aandu drugg administration (fda) rettifaanlimaabinte surakshyum falapraptiyum vilayiruthiyathu podiyam-201 (enn. sii. tii. 03599713) adisthaanamaakkiyulla oru ooppan-label, multy-regional, single-aam padanamaanu, metaastaattik allengil aavarthichulla praadeshikamaayi noothanamaaya emm. sii. sii ulla 65 pankaalikale vilayiruthunnu.
retifanlimab munganana avalokanam, phaast track, anatha mayakkumarunnu padavikal ennivaykkulla apeksha fda anuvadichu.
samoohavum samskaaravum.
perukal.
retifanlimab ennathu anthaaraashtra udamasthathayillaatha peraanu.